1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Gene Editing Therapy Casgevy Now Funded In 8 Countries But French Access Withdrawn

 
• By Eliza Slawther

The world’s first CRISPR gene editing therapy, Casgevy, has been made available to patients with sickle cell disease in England, adding to access arrangements in the US, Austria, Bahrain, Germany, Luxembourg, Italy and Saudi Arabia.

Casgevy is the first approved product to use CRISPR/Cas9 technology, which was identified as a gene editing tool in 2012. (Shutterstock)
Key Takeaways
  • Vertex’s CRISPR/Cas9 gene editing therapy Casgevy has been made available in England for patients with sickle cell disease, adding to access agreements in the US, Austria, Bahrain, Germany, Luxembourg, Italy and Saudi Arabia.
  • In France, Vertex previously had an early access arrangement for Casgevy in two indications, but it has since withdrawn from these arrangements.
  • The product is the world’s first CRISPR/Cas9 gene editing therapy to gain regulatory approval, and Vertex says it has seen strong interest in the therapy from eligible patients.

England’s health technology assessment (HTA) agency, NICE, has formally agreed to reimburse Vertex/CRISPR Therapeutics AG’s CRISPR/Cas9-based gene editing therapy Casgevy (exagamglogene autotemcel), also known as exa-cel, to treat...

On 31 January, NICE announced that Casgevy had been approved for use on the National Health Service in England for patients with severe SCD aged 12 years and over who...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Government Payers

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.